References
- Ghalamkarpour F, Baradaran-Rafii A, Sadoughi MM, et al. Ocular findings in patients with psoriasis: is it related to the side effects of treatment or to psoriasis itself? A case-control study. J Dermatol Treat. 2020;31(1):27–32.
- Maier H, Honigsmann H. Concentration of etretinate in plasma and subcutaneous fat after long-term acitretin. Lancet. 1996;348(9034):1107.
- Sturkenboom MC, de Jong-Van Den Berg LT, van Voorst-Vader PC, et al. Inability to detect plasma etretinate and acitretin is a poor predictor of the absence of these teratogens in tissue after stopping acitretin treatment. Br J Clin Pharmacol. 1994;38(3):229–235.
- Beltran F, Betancourt NR, Martinez J, et al. Transcultural validation of ocular surface disease index (osdi) questionnaire for mexican population. Investig Ophthalmol Vis Sci. 2013;54(15):6050.
- Midorikawa-Inomata A, Inomata T, Nojiri S, et al. Reliability and validity of the Japanese version of the Ocular Surface Disease Index for dry eye disease. BMJ open. 2019;9(11):e033940.
- Pakdel F, Gohari MR, Jazayeri AS, et al. Validation of Farsi translation of the ocular surface disease index. J Ophthalmic Vis Res. 2017;12(3):301–304.